Clinical Trials
3,235 trialsSBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Fudan University
Avatrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
KeyPemls-004
Peking Union Medical College Hospital
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
West China Hospital
Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
Peking Union Medical College Hospital
ROSALINE
Jules Bordet Institute
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Qilu Hospital of Shandong University
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Lu-DOTA-TATE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors
Suzhou Genhouse Bio Co., Ltd.
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
CaboACC
Wuerzburg University Hospital
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CESM
European Institute of Oncology
NANORAD2
University Hospital, Grenoble
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
FAPI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
Northwestern University
The Effect of Probiotics ATG-F4 in Cancer Patients
Chungnam National University Hospital
Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer
Zhejiang Cancer Hospital
Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy
Sir Run Run Shaw Hospital
SUNRISE
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RELEVENT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
Case Comprehensive Cancer Center
PM-CARE
IRCCS San Raffaele
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Shanghai Zhongshan Hospital
LungCadX
Shanghai Pulmonary Hospital, Shanghai, China
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
NeoTENNIS
Fudan University
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
GALAXY-1
The First Affiliated Hospital of Guangzhou Medical University
Effect of Vitamin C on Postoperative Pulmonary Complications After Intracranial Tumor Surgery
Qianfoshan Hospital
Nim-PC-28
Peking University Third Hospital
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Emory University
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Fudan University
SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy
Zhejiang Cancer Hospital
SABR-PDL1
Gustave Roussy, Cancer Campus, Grand Paris
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
NAPSTER
Peter MacCallum Cancer Centre, Australia
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Sir Run Run Shaw Hospital
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
MUKnineb
University of Leeds
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients
Rigshospitalet, Denmark
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
Tianjin Medical University Cancer Institute and Hospital
ANIMATE
University College, London
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
University of Liege